In the field of minimally invasive surgery, ultrasonic scalpel equipment has been monopolized by imported brands for a long time. Relying on their first-mover technological advantages, mature product systems and deep market accumulation, international brands firmly control the procurement channels of the high-end medical market of tertiary hospitals, forming an unshakable market pattern. The high cost of equipment procurement and consumables has made this technology, which should be universally beneficial, a “luxury product” in primary hospitals, and has also shifted the heavy medical burden to patients.
Breaking through the Dilemma: The Rise of Domestic Ultrasonic Surgeons
Faced with the dual dilemmas of technical barriers and market monopoly, Chinese medical device companies have risen to the challenge. In the absence of technical accumulation, early explorers started from scratch to overcome key technical problems such as cutter head materials and energy control, laying the foundation for the development of domestic ultrasonic scalpels. However, due to the difficulty of breakthroughs in core technology, domestic ultrasonic scalpel products have long been stuck in the mid- to low-end market.
As the country’s “14th Five-Year Plan” clearly proposes to break through core technologies and promote the localization of high-end medical equipment, and the medical insurance centralized procurement policy tilts towards domestic equipment, a series of benefits have injected strong impetus into the development of the industry. Driven by the two wheels of policy and market, domestic ultrasonic scalpel companies have ushered in a golden period of technological breakthroughs. Some ultrasonic scalpel companies with core technical advantages have begun to emerge, and the key performance and market share of domestic ultrasonic scalpels have continued to increase.
The End of Technology: Radiofrequency Ultrasound Redefines Industry Standards
In this tough battle, the radiofrequency ultrasonic scalpel of Wuhan Half the Sky Medical Technology Development Company has become a key game-breaker. As one of the earliest medical device companies in China to engage in independent research and development of ultrasonic scalpels, Wuhan Half the Sky has been focusing on technological innovation in the field of minimally invasive medical treatment since its establishment in 2002, and constantly exploring the boundaries of ultrasonic scalpel technology.
The company boldly innovated and integrated the two energy platforms of ultrasound and radio frequency to develop a radio frequency ultrasonic scalpel system with dual energy output. This innovative achievement successfully solved the “7 mm blood vessel closure” problem that has troubled the industry for many years, and obtained the first relevant registration certificate in China, filling the domestic technical gap in this field.
Wuhan Bantiantian radio frequency ultrasonic scalpel system uses one host machine and one blade, which can output ultrasonic waves and high-frequency electricity at the same time, accurately cut and stop bleeding of soft tissues, and coagulate large blood vessels with a diameter of ≤7mm. The product combines bipolar coagulation function and quick-change knife tube technology. Clinical data and professional testing institutions have proven that its key performance indicators such as cutting speed, coagulation function and thermal damage control have reached the international advanced level. This technological breakthrough has completely ended the technological hegemony of imported ultrasonic scalpel brands and redefined industry standards.
Market reshaping: from domestic substitution to global competition
Relying on its hard-core technical advantages, Wuhan Half-Sky’s radiofrequency ultrasonic scalpel products have entered more than 800 hospitals across the country, covering 30 provinces, autonomous regions and municipalities, and have passed EU CE certification. They have successfully entered international markets such as Europe, Southeast Asia, and the Middle East, achieving leapfrog development from domestic substitution to global competition. In the centralized procurement of multiple provincial alliances in 2024, the company’s products successfully won the bid with higher cost performance, marking that the dual advantages of “cost performance + technical strength” of domestic ultrasonic scalpels were officially recognized, setting a benchmark for domestic substitution in the entire industry.
At this point, China’s ultrasonic scalpel market has officially bid farewell to the era dominated by imported technology. Domestic medical device companies, represented by Wuhan Half the Sky, are transforming from “substitutes” to “definers” of industry standards. The global market structure is also moving from import dominance to domestic leadership. A “golden age” for China’s high-end medical devices is accelerating.
